Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MF59-adjuvanted H5N1 Influenza Vaccines
NCT00814385Phase 2Completed
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Nov 2008
- Primary completion
- Sep 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated) (9 arms), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoint: Geometric mean antibody titres at 56 weeks. Started Nov 2008; status: completed.
02
Drugs
Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
Beyond the preview
Go deeper on NCT00814385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814385.